The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01
AM Senderowicz - The oncologist, 2002 - academic.oup.com
AM Senderowicz
The oncologist, 2002•academic.oup.comAbstract Learning Objectives After completing this course, the reader will be able to:
Describe the basics of cell-cycle regulation. Understand how Rb pathway derangement
causes cancer. Relate the clinical findings with flavopiridol and UCN-01 to their mechanisms
of action. Access and take the CME test online and receive one hour of AMA PRA category 1
credit at CME. TheOncologist. com Many tumor types are associated with genetic changes in
the retinoblastoma pathway, leading to hyperactivation of cyclin-dependent kinases and …
Describe the basics of cell-cycle regulation. Understand how Rb pathway derangement
causes cancer. Relate the clinical findings with flavopiridol and UCN-01 to their mechanisms
of action. Access and take the CME test online and receive one hour of AMA PRA category 1
credit at CME. TheOncologist. com Many tumor types are associated with genetic changes in
the retinoblastoma pathway, leading to hyperactivation of cyclin-dependent kinases and …
Learning Objectives
After completing this course, the reader will be able to:
- Describe the basics of cell-cycle regulation.
- Understand how Rb pathway derangement causes cancer.
- Relate the clinical findings with flavopiridol and UCN-01 to their mechanisms of action.
Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com
Many tumor types are associated with genetic changes in the retinoblastoma pathway, leading to hyperactivation of cyclin-dependent kinases and incorrect progression through the cell cycle. Small-molecule cyclin-dependent kinase inhibitors are being developed as therapeutic agents. Of these, flavopiridol and UCN-01 are being explored in cancer patients in phase I and phase II clinical trials, both as single agents and in combination with conventional chemotherapeutic agents. The present article discusses the mechanisms of action of flavopiridol and UCN-01 as well as the outcome of clinical trials with these novel agents.
Oxford University Press